Key facts
- Chugai Pharmaceutical will invest approximately 100 billion yen ($635 million) annually in facilities and equipment by 2028.
- The company aims to reduce outsourcing and increase in-house production.
- Chugai will build a new research lab at its Ukima plant in Tokyo.
Chugai Pharmaceutical, a unit of Roche, plans to significantly increase its capital expenditure to bolster in-house production and reduce reliance on external manufacturers. The Japanese drugmaker intends to invest around 100 billion yen ($635 million) annually in facilities and equipment through 2028. This strategic shift is driven by a desire to cut costs associated with outsourcing. As part of this initiative, Chugai will construct a new research laboratory at its Ukima plant in Tokyo.